Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Natthakan Thongon, PhD, Christopher Jackson, BS, Pamela Lockyer, MS, Jintan Liu, Andrea Santoni, PhD, Ashley Rose, BS, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2019) 134 (Supplement_1): 685.

https://doi.org/10.1182/blood-2019-129286

Published: 2019

Journal Articles

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Wenqun Zhang, MD, Bo Hu, MD, Ling Jing, MD, Jing Yang, MD, Shan Wang, MD, Yang Liu, MD, Juan Du, MD, Yaoliang Ren, MD, Yonghong Zhang, MD

Blood (2019) 134 (Supplement_1): 1945.

https://doi.org/10.1182/blood-2019-125753

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD) - a Mechanistic Study

Ka Lam Nelson Ng, PhD, Claire Lynn, Thomas Wing Yan Leung, Eric Chi Wai So, PhD, Anskar Yu Hung Leung, MD PhD

Blood (2019) 134 (Supplement_1): 1261.

https://doi.org/10.1182/blood-2019-129472

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS

Blood (2019) 134 (Supplement_1): 3779.

https://doi.org/10.1182/blood-2019-131364

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD

Blood (2019) 134 (Supplement_1): 3756.

https://doi.org/10.1182/blood-2019-125355

Published: 2019

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Geethu Emily Thomas, PhDMSc,BSc, Grace Egan, MD, Laura Garcia Prat, Boaz Nachmias, MD PhD, Jordan M Chin, Fieke W Hoff, BSc, Kerstin Kaufmann, PhD, Rose Hurren, BSc, Marcela Gronda, MSc, Neil MacLean, Xiaoming Wang, Veronique Voisin, PhD, Aaron Botham, Andrea Arruda, Mark D. Minden, MD PhD, Gary D Bader, Steven M. Kornblau, MD, John E. Dick, PhD, Aaron D Schimmer, MD PhD

Blood (2019) 134 (Supplement_1): 2532.

https://doi.org/10.1182/blood-2019-123121

Published: 2019

Journal Articles

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Haruka Hiroki, MD, Masatoshi Takagi, MD PhD, Yuko Ishi, MD, Jinhua Piao, Tomohiro Morio, MD PhD

Blood (2019) 134 (Supplement_1): 3367.

https://doi.org/10.1182/blood-2019-127853

Published: 2019

Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 3107.

https://doi.org/10.1182/blood-2019-128245

Published: 2019

Journal Articles

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Tyler Maclay, Joseph Vacca, Casey McComas, Alfredo Castro, Melinda Day, PhD, Kevin Mills, PhD

Blood (2018) 132 (Supplement 1): 3963.

https://doi.org/10.1182/blood-2018-99-119373

Published: 2018

Journal Articles

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Claire Fritz, Scott M. Portwood, MS, MBA, Julie Adams, BS, Tara Cronin, BA, Linda Lutgen-Dunckley, Brandon L Martens, BS, Callum M. Sloss, PhD, Krystal Watkins, Yelena Kovtun, PhD, Sharlene Adams, PhD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 2647.

https://doi.org/10.1182/blood-2018-99-117214

Published: 2018

Journal Articles

LMO2 Facilitates Synthetic Lethality after PARP Inhibition (PARPi) in Diffuse Large B-Cell Lymphoma (DLBCL)

Ramiro E Verdun, PhD, Salma Parvin, PhD, Ariel Ramirez Labrada, PhD, Gabriel Emmanuel Santiago, Cortizas M Elena, Sharabi Eden, Aumann Shlomzion, MD, Zhang Yu, PhD, Isidro Sanchez-Garcia, PhD, Francisco Vega, MD PhD, Jennifer Rose Chapman-Fredricks, MD, Izidore S. Lossos, MD

Blood (2018) 132 (Supplement 1): 674.

https://doi.org/10.1182/blood-2018-99-110825

Published: 2018

Journal Articles

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Blood (2018) 132 (Supplement 1): 769.

https://doi.org/10.1182/blood-2018-99-118047

Published: 2018

Journal Articles

CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition

Miguel Quijada Álamo, BSc, MSc, María Hernández-Sánchez, PhD, José Luis Ordóñez, PhD, Verónica Alonso Pérez, PhD, Ana E. Rodriguez, PhD, Ignacio García-Tuñón, PhD, Ana B Herrero, PhD, Laura San-Segundo, Michaela Gruber, MD PhD, Juan Luis García, PhD, Rocio Benito, PhD, Catherine J. Wu, MD, Jesús-María Hernández-Rivas, MD PhD

Blood (2018) 132 (Supplement 1): 948.

https://doi.org/10.1182/blood-2018-99-116080

Published: 2018

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions

Margaret Nieborowska-Skorska, Paulina Podszywalow-Bartnicka, Silvia Maifrede, Bac Viet Le, Monika Toma, Peter Valent, Tomasz Sliwinski, Wayne Childers, Katarzyna Piwocka, Alexei Tulin, Tomasz Skorski, MD PhD

Blood (2018) 132 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2018-99-115041

Published: 2018

NARROW

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD) - a Mechanistic Study

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

LMO2 Facilitates Synthetic Lethality after PARP Inhibition (PARPi) in Diffuse Large B-Cell Lymphoma (DLBCL)

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only